Literature DB >> 10801212

Clinical trial simulation in drug development.

P L Bonate1.   

Abstract

Clinical trial simulation is the application of old technologies, e.g., Monte Carlo simulation, to a new problem, that problem being how to maximize the information content obtained during the drug development process with an intent to have the greatest chance of "success" in a clinical trial. When the information content of the drug is high, then simulation provides a method to synthesize that information into a coherent package that indicates the sponsor has good control over the pharmacology of the drug. From a purely financial point of view, what simulation offers pharmaceutical companies is the possibility of reducing the number of required studies, maximizing the chances for success in a clinical trial, and possibly shortening development time; all outcomes which will reduce drug development costs. The purpose of this paper is to introduce clinical trial simulation to the reader by discussing its potential in drug development, to briefly review the literature, and to make recommendations and caveats regarding its use.

Mesh:

Year:  2000        PMID: 10801212     DOI: 10.1023/a:1007548719885

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  A brief introduction to Monte Carlo simulation.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.

Authors:  Peter A Lockwood; Jack A Cook; Wayne E Ewy; Jaap W Mandema
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 4.  Role of modelling and simulation: a European regulatory perspective.

Authors:  Siv Jönsson; Anja Henningsson; Monica Edholm; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 5.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 6.  Role of pharmacoeconomic analysis in R&D decision making: when, where, how?

Authors:  Paul Miller
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Evidence of effectiveness: how much can we extrapolate from existing studies?

Authors:  Howard Lee; Dong-Seok Yim; Honghui Zhou; Carl C Peck
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

8.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors:  Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria.

Authors:  Angela Matthews; Trevor N Johnson; Amin Rostami-Hodjegan; Anupam Chakrapani; J Edward Wraith; Stuart J Moat; James R Bonham; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.